---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-038602"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2025-12-23T23:59:59+00:00"
generated_at: "2026-05-16T12:16:34.623653+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA requires second Phase 3 trial for Reviva's brilaroxazine in schizophrenia; NDA delayed to late 2027

## Summary
- FDA recommends RECOVER-2 Phase 3 trial (30/50 mg) before NDA submission; similar to RECOVER design.
- RECOVER-2 initiation planned H1 2026, data Q2 2027; NDA target Q4 2027, potential approval Q4 2028; est. cost ~$60M.
- Stockholders approved authorized share increase from 315M to 515M and reverse stock split (1:2 to 1:20, Board discretion).
- Warrant exercises Oct–Dec 2025: 19.8M shares, ~$6.7M net; cash ~$14.7M as of Dec 16, sufficient through Q2 2026 ex-RECOVER-2.
- Long-term safety data from RECOVER open-label extension over 52 weeks shows favorable tolerability and adherence.

## SEC filing metadata
- accession: 0001437749-25-038602
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2025-12-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.03, 5.07, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774925038602/0001437749-25-038602-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774925038602/rvph20251216_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-038602
- JSON: https://secwatch.observer/filing/0001437749-25-038602.json
- Plain text: https://secwatch.observer/filing/0001437749-25-038602.txt

## Source-grounded claims
- claim_id: 6d196f616325b44dacb502d951a8d0cb15c46d93
  claim: REVIVA PHARMACEUTICALS HOLDINGS, INC.: Stockholders approved an amendment to the Certificate of Incorporation to increase authorized shares of Common Stock from 315,000,000 to 515,000,000, filed and effective December 18, 2025 (effective 2025-12-18).
  evidence_excerpt: On December 18, 2025, the Company filed the Increase in Authorized Charter Amendment with the Secretary of State of the State of Delaware and such amendment became effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774925038602/0001437749-25-038602-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.